All News
Filter News
Found 808,689 articles
-
Lentechs Announces Successful $6 Million Fundraise to Further Key Development Objectives
10/24/2023
Lentechs announced the closing of a successful fundraise to further key development objectives for its investigational contact lens for patients with presbyopia.
-
Merck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List
10/24/2023
We're proud to celebrate Sarah M. Aiosa, SVP and president, Latin America, for being recognized as one of The Association of Latino Professionals for Americas' 2023 Most Powerful Latinas!
-
FDA Roundup: October 24, 2023
10/24/2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
10/24/2023
Caris Life Sciences® announced a new agreement with Moderna in support of Moderna's oncology and novel therapeutics initiatives.
-
ProfoundBio to Participate in the Wells Fargo 2023 Virtual Private Biotech Symposium and Piper Sandler 35th Annual Healthcare Conference
10/24/2023
ProfoundBio announced that management will be participating in one-on-one meetings with investors at the Wells Fargo 2023 Virtual Private Biotech Symposium on Wednesday, November 1, 2023 and at the Piper Sandler 35th Annual Healthcare Conference from November 28 – November 30, 2023.
-
Lecanemab named one of the world's best inventions in 2023 by TIME
10/24/2023
BioArctic AB and partner Eisai are proud to announce that TIME has selected lecanemab as one of the Best Inventions of 2023 in the medical care category.
-
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
10/24/2023
Vivos Therapeutics, Inc. has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services for approximately 1.8 million patients.
-
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
10/24/2023
argenx announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET to discuss its third quarter 2023 financial results and provide a business update.
-
3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations
10/24/2023
Q3 results reflect strong operational execution, restructuring actions, and proactive spending discipline.
-
Experienced Business Development Leader Joins Sage Product Development, Inc. in Key Vice President Role
10/24/2023
Sage Product Development, Inc., a leading medical device contract product development and early-stage manufacturing firm, is excited to announce the appointment of Laurie Bourgeois as Vice President of Business Development.
-
Kamiyacho Neurosurgical Clinic in Japan Celebrates First Brain Tumor Patient Treated with the New ZAP-X® Gyroscopic Radiosurgery® Platform
10/24/2023
ZAP Surgical, a leading innovator in the field of surgical robotics, announced the first patient treatment using the groundbreaking ZAP-X® Gyroscopic Radiosurgery® platform at Kamiyacho Neurosurgical Clinic in Tokyo, Japan.
-
Five-Year Data From Partner 3 Trial Demonstrate Excellent Survival for Patients Receiving Edwards Sapien 3 Valve
10/24/2023
Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years.
-
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
10/24/2023
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia.
-
Jefferies to Host 14th Annual Global Healthcare Conference in London
10/24/2023
Jefferies looks forward to welcoming delegates back to its 2023 London Healthcare Conference, taking place in-person from Tuesday, November 14 to Thursday, November 16.
-
Radiaction Medical Appoints Christopher Barys as New US President and Chief Commercial Officer - October 24, 2023
10/24/2023
Radiaction Medical, LTD announced that it has appointed industry veteran Christopher Barys to serve as its US President and Chief Commercial Officer.
-
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
10/24/2023
SAB Biotherapeutics , Inc. (Nasdaq: SABS ), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) that may delay the onset or progression of type 1 diabetes (T1D).
-
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
10/24/2023
Annexon, Inc. announced that the European Medicines Agency has granted Priority Medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration.
-
Globus Medical Schedules 2023 Third Quarter Earnings Release and Conference Call
10/24/2023
Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2023 after the market close on Tuesday, November 7, 2023.
-
Lung Cancer Mutation Consortium LEADER Trial Enrolls 100th Patient
10/24/2023
The Lung Cancer Mutation Consortium, facilitated by the Lung Cancer Research Foundation, announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer, examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.
-
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/24/2023
IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.